Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Chinese pharmaceuticals maker China Sky One Medical (NASDAQ:CSKI) has earned a respected four-star ranking.

With that in mind, let's take a closer look at China Sky One's business and see what CAPS investors are saying about the stock right now.

China Sky One facts

Headquarters (Founded)

Harbin, China (1994)

Market Cap

$222.0 million

Industry

Personal products

Trailing-12-Month Revenue

$112.7 million

Management

Chairman/CEO Yan-Qing Liu

CFO Yu-Bo Hao

Return on Equity (Average, Past 3 Years)

41%

Cash / Debt

$48.2 million / $0

Other Highly Rated Drug Stocks

Pfizer (NYSE:PFE)

Merck (NYSE:MRK)

GlaxoSmithKline (NYSE:GSK)

CAPS Members Bullish on CSKI Also Bullish on

Vale (NYSE:VALE)

American Oriental Bioengineering (NYSE:AOB)

CAPS Members Bearish on CSKI Also Bearish on

Shanda Interactive (NASDAQ:SNDA)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 211 members who have rated China Sky One believe the stock will outperform the S&P 500 going forward. These bulls include All-Star SpartanMAC and balabanovj.

Just yesterday, SpartanMAC listed several reasons why China Sky would eventually fly high: "There is no long term debt here, over 35% insider ownership, strong EPS / Revenue growth rates over the past 3 years, and strong overall growth projections for the future. Price to book is less than 3, and a very strong balance sheet."

In an earlier pitch from January, balabanovj soars even deeper into the sky:

This is the one China pharma/biotech that I don't have a single reservation about -- they're simply doing everything right. While they specialize in OTC drugs, they are making inroads into prescription and injectables as well, and have their fingers in numerous research joint projects on new drugs. They are also wildly profitable and have a very aggressive marketing program. ... Company growth is also heavily organic and they are miserly with their shares when making acquisitions.

What do you think about China Sky One, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. The CAPS community is waiting to hear your opinions. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick. Shanda Interactive Entertainment is a Rule Breakers selection. American Oriental Bioengineering is a Motley Fool Hidden Gems and Global Gains selection. The Fool owns shares of American Oriental. The Fool's disclosure policy always gets a perfect score.